Shell/AstraZeneca release Q1 IFRS numbers

Shell and AstraZeneca, two of the biggest FTSE100 companies, presented their first numbers under new international accounting standards today, and morning trading suggests that the market has responded confidently to the new figures.

Link: Restatement sees Rolls-Royce share price soar

Pharmaceutical company AstraZeneca, the makers of Nolvadex and Exanta, reported a 34% increase in operating profit at constant exchange rates.

The drug company saw Q1 operating profits increase from $1.05bn in 2004 to $1.4bn in 2005. The 2004 figures had been restated under IFRS for comparative purposes. The company’s share price responded positively, climbing from just under 2,300p to around 2,350p.

Shell, meanwhile, reported a 42% increase in income for Q1 2005. The oil behemoth’s income rose from $4.7bn in Q1 2004 to $6.7bn in 2005. The company was also using restated 2004 IFRS accounts for its comparisons. Shell’s share price traded in around the 467.5p to 470p range after the announcement.

Related reading

PwC office 2